Malabsorption Is Uncommon in Restless Legs Syndrome

Celiac disease (CD), which is one of the most important malabsorptive diseases in adults, has been associated with several neurological disorders including peripheral neuropathy, cerebellar ataxia, myopathy, and attention deficit hyperactivity disorders. Recently, 2 independent studies reported a high prevalence of restless legs syndrome (RLS) in CD patients (23%–31%). In the first study, iron deficiency was present in 40% of CD patients with active RLS compared with 6% of patients without RLS, whereas in the second study, no significant correlation was found between RLS and iron parameters. Other authors reported 4 patients with RLS and serum ferritin below 25 ng/mL whose screening tests were positive for CD. Because these data suggest that CD is frequently associated with RLS and because CD could be an underlying correctable factor for some patients diagnosed with idiopathic RLS, we evaluated the absorptive status in 112 consecutive patients referred to our Sleep Disorders Center (68 women, 44 men; mean age, 59.6 years) with a diagnosis of idiopathic RLS. The diagnosis of RLS was made by face-to-face interview using International Restless Legs Syndrome Study Group (IRLSSG) criteria. In our patients, mean RLS severity according to the IRLSSG rating scale was 24.9 (range, 10–38). Using current criteria, CD diagnosis was based on the presence of specific screening antibodies in serum (antitransglutaminase IgAtTG) and on the evidence of intestinal damage at duodenal biopsy.

For investigating malabsorption in our RLS patients, the following typical symptoms and signs of CD were considered: abdominal pain, anorexia, diarrhea, flatulence, muscle wasting, vomiting, and weight loss. Moreover, all patients were tested for anti-tTG antibodies with the Eu-tTG Quick test (reference 9113, lot 3368, Eurospital). Symptomatic and signs of malabsorption in our RLS patients were uncommon (diarrhea in 14.3%, flatulence in 3.6%, abdominal pain in 1.8%).

In our sample, only 2 patients affected by CD (1.8%) were found: a woman (age 57 years; body mass index, 23.3; serum ferritin level, 9 ng/mL; IRLSSG rating scale score = 18) positive for anti-tTG antibodies by the eu-tTG Quick Test (CD diagnosis confirmed by duodenal biopsy) and another woman (age 74; body mass index, 18.0; serum ferritin level, 15 ng/mL; IRLSSG rating scale score = 38) whose Eu-tTG Quick test was negative because of a gluten-free diet, but with a previous diagnosis of CD confirmed by duodenal biopsy. No cause for the iron deficiency was found in these 2 cases other than CD. Both patients had a family history positive for RLS. The first patient had never received specific treatments for RLS, whereas the second patient had used only clonazepam (0.5 mg/day) for several months without significant effect on her RLS symptoms.

In the first patient, a gluten-free diet and supplemental iron (4 treatments of 200 mg of intravenous iron sucrose spread over 1 week) determined an increase in serum ferritin level to 46 ng/mL without any significant improvement in RLS symptoms (IRLSSG rating scale score = 15). The second patient, already on a gluten-free diet, with the supplemental iron (5 treatments of 200 mg of intravenous iron sucrose spread over 1 week) had an increase in serum ferritin (39 ng/mL) with a concomitant marked improvement in RLS (IRLSSG rating scale score = 13).

The currently estimated prevalence of CD is 1%, with a statistical range of probability of 0.5%–1.26% in the general population in Europe and the United States. In our sample of consecutive patients with RLS, the prevalence of CD was 1.8%; thus, it is very difficult to state that CD is frequently associated with RLS. By observing our cases, we cannot conclude that gluten withdrawal determined an improvement in RLS symptoms. In both our patients we observed very low ferritin levels, and this seems to suggest that CD may be associated with RLS because of an association with iron deficiency. However, in a previous study in a CD population, we found lower hemoglobin levels in CD patients with RLS than in those without RLS, but no significant correlation between the presence of RLS and iron metabolism. Finally, the marked improvement observed in our second patient suggests that before providing specific treatments with dopaminergic compounds for RLS, a gluten-free diet and supplemental iron should be considered in patients with RLS plus CD.

Luigi Ferini-Strambi, MD, Sara Marelli, PhD, Marcello Moccia, MS, Roberto Erro, MD, Carolina Ciacci, MD, and Paolo Barone, PhD

1Sleep Disorders Center and Division of Neurosciences, Università Vita-Salute San Raffaele, Milan, Italy; 2Department of Neurological Sciences, University Federico II, Naples, Italy; 3Department of Systematic Pathology, University Federico II, Naples, Italy; and 4Department of Neurological Sciences, University Federico II, Naples, Italy

References

Novel Mutations in Siblings with Later-Onset PLA2G6-Associated Neurodegeneration (PLAN)

Mutations in the PLA2G6 gene were first described in individuals with infantile neuroaxonal dystrophy (INAD) in 2006 and were later described in individuals presenting with dystonia and parkinsonism in the late teenage years and early adulthood. It has been proposed that the spectrum of neurodegenerative disorders related to mutations in the PLA2G6 gene be called "PLA2G6-associated neurodegeneration" (PLAN). We describe 2 siblings with MRI findings of cerebellar atrophy and brain iron accumulation and a clinical presentation consistent with the adult-onset dystonia-parkinsonism phenotype described in some reports.

Patients and Methods

Both siblings were born to nonconsanguineous parents of French, German, Irish, and English ancestry. Sibling 1 first developed depression requiring hospitalization at age 18 but was able to complete 2 years of community college with a B average. Subsequently, she developed difficulty with mobility, a tendency to fall, and softened speech.

Her examination at age 20 revealed hypophonia, appendicular and axial rigidity, stooped posture with shuffling gait, accompanying dystonic posturing of her limbs, brisk reflexes, negative Babinski, and positive Romberg. She is currently 26 years old, and her course over the past 6 years has been marked by increasing rigidity, progressive hypophonia, and profound postural impairment.

Sibling 2 was reported to be normal until age 4, when she developed stuttered speech, dyslexia, and clumsiness. Behavioral difficulties such as poor eye contact and difficulty with authority figures were noted. Her motor skills stabilized with therapy through high school. At age 17, she developed psychiatric symptoms including delusions and paranoia. Her examination at age 23 years revealed a flat affect, a withdrawn demeanor with paucity of speech, hypophonia, and masked facies. She had saccadic pursuits without nystagmus and dystonic hand posturing. Her tone was increased with some accompanying contractures that reduced the range of motion. A fine distal hand tremor was present. Ankle reflexes were absent with negative Babinski. Her upper extremities were slow and dysmetric on targeted movements. The patient required support at all times while ambulating.

PLA2G6 Testing Methods

All 16 coding exons of the PLA2G6 gene were bidirectionally sequenced in sibling 1. Sequencing of exon 2 was performed on parents and sibling 2. All family members were screened using multiplex ligation-dependent probe amplification (MLPA). Analysis was performed using SALSA MLPA kit P120 PANK2/PLA2G6 (MRC-Holland, Amsterdam, The Netherlands).

Results

Imaging

T1-weighted MRI imaging demonstrated significant cerebellar atrophy in both siblings (Fig. 1B,D). T2-weighted
images demonstrated bilateral hypointensity of the globus pallidus in both siblings (Fig. 1A,C).

PLA2G6 Testing

Sequence analysis in both sisters revealed a heterozygous c.4C>A substitution in exon 2 of the PLA2G6 gene. This nucleotide change causes a substitution of lysine for a highly conserved glutamine at the second amino acid of the iPLA2-VIA protein (p.Q2K).

MLPA analysis revealed a heterozygous deletion of exon 3 in both sisters. The deletion of exon 3 does not alter the reading frame of the remaining PLA2G6 transcript and is predicted to result in an in-frame deletion of amino acids 71-142.

Testing of the parents confirmed that these 2 mutations are present in the trans configuration in the siblings.

Discussion

We report 2 novel PLA2G6 mutations in siblings presenting with psychiatric and motor findings consistent with prior reports of PLA2G6-associated dystonia-parkinsonism. Both siblings had cerebellar atrophy and evidence of brain iron accumulation on MRI. These MRI findings have not been consistent in the limited number of later-onset PLAN patients described to date.1,2,3

A trend has been noted wherein later-onset PLAN disorders are associated with the presence of missense mutations.2,3 To date, this is the first report of a later-onset PLAN phenotype associated with a large deletion in the PLA2G6 gene. That the exon 3 deletion leaves the remaining reading frame intact may contribute to the milder presentation in these siblings. Previously, whole-exon deletions have only been reported in the more severe infantile neuronal dystrophy presentation of PLAN.4

One notable feature is the discrepancy in the age of onset of symptoms in the 2 siblings. This suggests that factors other than the PLA2G6 genotype may contribute to disease onset and progression.

Matthew A. Bower, MS, Khalaf Bushara, MD, MRCP, Melissa A. Dempsey, MS, Soma Das, PhD, and Paul J. Tuite, MD

1 Institute of Human Genetics and 2 Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA; and 3 Department of Human Genetics, University of Chicago, Chicago, Illinois, USA

References


Opsoclonus-Myoclonus Syndrome and Exaggerated Startle Response Associated With Small-Cell Lung Cancer

Opsoclonus-myoclonus syndrome (OMS) is a rare neurological disorder that is usually seen in conjunction with tumors (most commonly breast, lung, and gynecological), infections, or toxic-metabolic processes. In addition to opsonus and/or myoclonus, the clinical features of OMS may include ataxia and encephalopathy.1,2 We describe a patient who presented with OMS and a strikingly exaggerated startle response, prompting an evaluation for an underlying malignancy, which led to diagnosis of a small-cell lung carcinoma.

A 64-year-old woman presented with a 3-month history of dizziness and unsteadiness. Her symptoms began suddenly with an attack of dizziness and unsteadiness that lasted only a few seconds. The dizziness was described as a light-headed feeling without vertigo. Over the next few weeks, she had similar episodes, lasting longer and occurring more frequently, and eventually her symptoms became constant. Then, 2 weeks prior to her presentation, she developed “jumping” vision. The patient also had lost approximately 15 pounds over the past few months. She had a remote history of tobacco use. Before our evaluation she had a normal brain MRI.

On examination, the patient had bursts of back-to-back, multidirectional saccades, with variable amplitude (ie, opsonus), that were exacerbated during pursuit. The saccadic oscillations were also visible under closed eyelids (Video 1). She had occasional spontaneous myoclonic jerks of her head and a strikingly exaggerated startle response to sound and light that could be elicited even with expected stimuli (Video 2). Eye movements were otherwise remarkably intact. A subtle intention and postural tremor of her hands was present, as well as a slight dystonia in the left hand. Her gait was wide based and mildly unsteady, and she could not walk in tandem unassisted. The remainder of her examination was normal.

Routine blood studies showed no abnormalities. Cerebrospinal fluid analysis was normal. Viral PCR including for West Nile
virus was negative. An EEG was within normal limits, and when she was startled, there was no EEG correlate to her myoclonic jerk apart from muscle artifact. A comprehensive serum paraneoplastic antibody panel (including, among others, anti-Ri, -amphiphysin, -Yo, -CV2, and -Hu) was negative. A CT of the chest/abdomen/pelvis, mammograms, transvaginal ultrasound, and FDG-PET/CT were performed, and a 4.2-cm lung mass was found in the left lower lobe with involvement of 1 lymph node. A lung biopsy showed this to be a small-cell lung carcinoma. PET also revealed physiologically increased uptake in the cerebrum and in the cerebellar hemispheres, although more so in the latter. Treatment for the malignancy was initiated with combination chemotherapy and radiation therapy. Over the course of several months, her tumor shrank, her ocular oscillations markedly improved, and her startle myoclonus disappeared.

Paraneoplastic neurological syndromes are considered to arise from an autoimmune response directed against neuronal antigens ectopically expressed by tumor cells. Specific autoantibodies have been associated with OMS, especially anti-Ri and anti-amphiphysin, but most patients with OMS are seronegative for all known antineuronal antibodies, suggesting that cell-mediated immunity plays an important role. Alternatively, there may be associated novel autoantibodies yet to be identified.

Localization of the lesion in OMS remains controversial, with evidence supporting 2 predominant theories. One hypothesis states that cerebellar dysfunction leads to disinhibition of the fastigial nucleus by the Purkinje cells, resulting in OMS. Specific autoantibodies have been associated with OMS, especially anti-Ri and anti-amphiphysin, but most patients with OMS are seronegative for all known antineuronal antibodies, suggesting that cell-mediated immunity plays an important role.

Sleep-related rhythmic movement disorder (SRMD) encompasses a group of disorders characterized by stereotyped, repetitive, rhythmic movements involving different parts of the body emerging mainly during sleep onset. SRMD typically starts within the first 2 years of life and usually resolves by age 10. Adult cases are not uncommon, but familial occurrence is very rare. The pathogenesis of SRMD probably varies, given the various phenomena ranging from “autoerotic,” self-stimulatory behaviors during wake or sleep onset to more complex movements arising from stable sleep accompanied by sleep disruption that have been included under this category. However, cases studied with video-polysonmography (VPSG) have shown that some forms of SRMD constitute true movement disorders that emerge in relation to arousal events.

To gather information about the pathophysiology of SRMD, we studied a familial case of SRMD in a 24-year-old man persistent since infancy. The episodes had been observed by his parents, as he had no recollection of the events on awakening. The patient complained about frequent mild head injuries during sleep, nonrestorative sleep, and daytime sleepiness. He was born after an uncomplicated pregnancy, among others, anti-Ri, -amphiphysin, -Yo, -CV2, and -Hu was negative. A CT of the chest/abdomen/pelvis, mammograms, transvaginal ultrasound, and FDG-PET/CT were performed, and a 4.2-cm lung mass was found in the left lower lobe with involvement of 1 lymph node. A lung biopsy showed this to be a small-cell lung carcinoma. PET also revealed physiologically increased uptake in the cerebrum and in the cerebellar hemispheres, although more so in the latter. Treatment for the malignancy was initiated with combination chemotherapy and radiation therapy. Over the course of several months, her tumor shrank, her ocular oscillations markedly improved, and her startle myoclonus disappeared.

Paraneoplastic neurological syndromes are considered to arise from an autoimmune response directed against neuronal antigens ectopically expressed by tumor cells. Specific autoantibodies have been associated with OMS, especially anti-Ri and anti-amphiphysin, but most patients with OMS are seronegative for all known antineuronal antibodies, suggesting that cell-mediated immunity plays an important role.

Legends to the Videos

Video 1: Spontaneous saccadic oscillations, also visible with closed eyes, exacerbated with pursuit. The movements occurred intermittently, and there did not appear to be an intersaccadic interval.

Video 2: Exaggerated startle with blinking of the eyes and flexion of the neck to expected and unexpected auditory (clap) and visual (light) stimuli.

Elias S. Sotirchos, MD, E. Ray Dorsey, MD, MBA, Ik Lin Tan, MBBS, and David S. Zee, MD

1Medical School, National & Kapodistrian, University of Athens, Greece; 2Department of Neurology, Johns Hopkins University School of Medicine, Baltimore, Maryland, USA

References


A Familial Case of Sleep Rhythmic Movement Disorder Persistent Into Adulthood; Approach to Pathophysiology

Sleep-related rhythmic movement disorder (SRMD) encompasses a group of disorders characterized by stereotyped, repetitive, rhythmic movements involving different parts of the body emerging mainly during sleep onset. SRMD typically starts within the first 2 years of life and usually resolves by age 10. Adult cases are not uncommon, but familial occurrence is very rare. The pathogenesis of SRMD probably varies, given the various phenomena ranging from “autoerotic,” self-stimulatory behaviors during wake or sleep onset to more complex movements arising from stable sleep accompanied by sleep disruption that have been included under this category. However, cases studied with video-polysonmography (VPSG) have shown that some forms of SRMD constitute true movement disorders that emerge in relation to arousal events.

To gather information about the pathophysiology of SRMD, we studied a familial case of SRMD in a 24-year-old man persistent since infancy. The episodes had been observed by his parents, as he had no recollection of the events on awakening. The patient complained about frequent mild head injuries during sleep, nonrestorative sleep, and daytime sleepiness. He was born after an uncomplicated gestation and labor and had a normal psychomotor development and cognitive profile. He was taking no medications and denied any alcohol or substance abuse. His neurological status was unremarkable.

Additional Supporting Information may be found in the online version of this article.

*Correspondence to: Anastasios Bonakasis, Medical School, University of Athens, Department of Neurology, Eginition Hospital, Athens, Greece; bonakastasos@yahoo.com

Relevant conflicts of interest/financial disclosures: Nothing to report. Full financial disclosures and author roles may be found in the online version of this article.

Published online 29 April 2011 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.23627
history, clinical examination, and brain MRI were unremarkable. Family history revealed a 57-year-old maternal uncle still suffering from SRMD and a maternal grandfather with lifelong restless sleep.

The patient underwent 4 consecutive full-night Video-polygraphic recordings. The first was a diagnostic Video-PSG, and the rest included 24-lead EEG recordings (the last 2 made after nighttime administration of clonazepam 0.25 and 0.5 mg, respectively). Sleep was scored in 30-second epochs according to the new AASM criteria. Video-PSG revealed body-rolling movements in stages 1 and 2 and REM sleep. Periodically, rhythmic movements of the right upper limb hitting the forehead were recorded (Video). No other sleep pathology was detected.

Sleep data from the second (clonazepam-free), third (clonazepam 0.25 mg), and fourth (clonazepam 0.5 mg) night recordings as well as information (number, duration, etc.) about the rhythmic movement episodes (RMs) are presented in Table 1.

During the clonazepam-free night record, most RMs occurred in REM sleep. The RMs in REM sleep were similar to those in non-REM sleep (NREM), but their duration was very brief (from 4 to 20 seconds) compared with those reported in NREM sleep (from 16 to 460 seconds) (Video, Fig. 1a). The majority of RMs that took place during NREM were preceded by an arousal. However, there were RMs that emerged from stable stage 2 sleep (Fig. 1b).

### Table 1. Sleep data from second-night (clonazepam-free), third-night (clonazepam 0.25 mg), and fourth-night (clonazepam 0.5 mg) recordings as well as the number of rhythmic movement episodes, their total and longest duration, and their relation to REM stage

<table>
<thead>
<tr>
<th></th>
<th>Second night</th>
<th>Third night</th>
<th>Fourth night</th>
</tr>
</thead>
<tbody>
<tr>
<td>SP</td>
<td>533</td>
<td>530.5</td>
<td>588.5</td>
</tr>
<tr>
<td>TST</td>
<td>530.5</td>
<td>528.5</td>
<td>582.5</td>
</tr>
<tr>
<td>SE (%)</td>
<td>96.2</td>
<td>95.2</td>
<td>96.9</td>
</tr>
<tr>
<td>N1 % of SP</td>
<td>8.3</td>
<td>4.6</td>
<td>5.3</td>
</tr>
<tr>
<td>N2 % of SP</td>
<td>59</td>
<td>58.5</td>
<td>52.3</td>
</tr>
<tr>
<td>N3 % of SP</td>
<td>8.5</td>
<td>12.9</td>
<td>14.2</td>
</tr>
<tr>
<td>REM % of SP</td>
<td>23.7</td>
<td>20.9</td>
<td>27.2</td>
</tr>
<tr>
<td>W % of SP</td>
<td>0.5</td>
<td>3.1</td>
<td>1</td>
</tr>
<tr>
<td>ARI</td>
<td>15.5</td>
<td>11.9</td>
<td>15</td>
</tr>
<tr>
<td>RMs, total number</td>
<td>22</td>
<td>53</td>
<td>43</td>
</tr>
<tr>
<td>RMs in REM</td>
<td>15</td>
<td>43</td>
<td>42</td>
</tr>
<tr>
<td>RMs related to arousal</td>
<td>6</td>
<td>3</td>
<td>5</td>
</tr>
<tr>
<td>TD (s)</td>
<td>1259</td>
<td>497.8</td>
<td>163</td>
</tr>
<tr>
<td>LD (s)</td>
<td>460</td>
<td>54.9</td>
<td>10.9</td>
</tr>
</tbody>
</table>

SP, sleep period; TST, total sleep time; SE, sleep efficiency; N1, sleep stage 1; N2, sleep stage 2; N3, slow-wave sleep; W, wake stage after sleep onset; ARI, arousal index; RMs, rhythmic movement episodes; TD, total duration of RMs; LD, longest duration of RMs.

**FIG. 1.** a: Short, rhythmic movement episode in REM sleep (30-second epoch, 2-upper-channel electrooculogram, 6-channel electroencephalogram; EKG, electrocardiogram; chin, electroencephalogram of submentalis muscle). b: Rhythmic movement episode emerging from stable sleep stage 2 (30-second epoch, 2-upper-channel electrooculogram, 6-channel electroencephalogram). c: Two epochs, 60 seconds each, of REM sleep with prolonged lack of muscle atonia as recorded from submentalis muscle (chin). The first epoch includes respiratory effort channels (abdomen, thorax), airflow (thermistor), and electromyography from left and right tibialis anterior muscles. The increased muscle tone is not related to an arousal stimulus.
contrast, almost no RMs emerging during REM were preceded by arousal. Concomitantly with the rhythmic movements, various other nonrhythmic movements (myoclonic or periodic) were apparent in stages 1–2, sometimes causing arousals followed by an RM (Video).

During REM sleep, periods of increased muscle tone unrelated to arousal stimuli were observed (Fig. 1c). This phenomenon of REM without atonia is characteristic of REM sleep behavior disorder (RBD). REM without atonia has been reported in SRMD cases persistent beyond infancy. Furthermore, RMD-like movements may emerge during episodes of RBD. In our case, it was clear that the patient did not have RBD, given that he did not exhibit dream enactment behavior, and the movements in REM sleep were of the body-rolling type, similar to those in NREM sleep.

After the administration of clonazepam, the number of RMs in NREM sleep decreased markedly, with the patient spending more time in slow-wave sleep (SWS). The patient reported enhanced functioning during daytime and feeling more refreshed on awakening. The increased SWS probably relates to the decrement of RMs, which results in less disrupted NREM sleep. Hence, the observed increase of SWS is an indirect effect of clonazepam. In contrast, the RMs significantly increased in REM sleep, leading to a higher total number of RMs compared with the clonazepam-free recording; however, the brevity of the events during REM sleep led to a marked reduction of the average and longest duration of the RMs. It seems that clonazepam had no effect on RMs emerging in REM sleep. After 1 year of follow-up, the patient continues to experience more restorative sleep and brief RMs despite the increment of clonazepam, up to 1 mg/night.

**Legends to the Video**

**Video Segment 1.** An episode of body rolling accompanied by rhythmic movement of the right upper limb during NREM stage 2 sleep.

**Video Segment 2.** An episode of body rolling preceded by a myoclonic jerk of the right latissimus dorsi muscle in stage 2 sleep.

**Video Segment 3.** Short-in-duration rhythmic movements in REM sleep.

**Acknowledgments:** We thank the sleep technicians of Evangelismos Hospital Sleep Center.

Anastasios Bonakis, MD, PhD, Ilia Kritikou, MD, Emmanouil Vagiakis, MD, Serafim Nanas, MD, and Sokratis G. Papageorgiou, MD, PhD

1 Medical School, University of Athens, Department of Neurology, Eginition Hospital, Athens, Greece; 2 Medical School, University of Athens, Department of Psychiatry, Eginition Hospital, Athens, Greece; 3 College of Medicine, Penn State University, Psychiatry Department, Sleep Research and Treatment Center, Hershey, Pennsylvania, USA; and 4 Evangelismos Hospital, Critical Care and Pulmonary Services, Center of Sleep Disorders, Athens, Greece
Table 1. Demographics and mutation frequency

<table>
<thead>
<tr>
<th></th>
<th>All subjects (n = 104)</th>
<th>All Hispanics (n = 19)</th>
<th>Puerto Ricans (n = 8)</th>
<th>Non-Puerto Rican Hispanics (n = 11)</th>
<th>Non-Hispanic whites (n = 85)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex, % female (n)</td>
<td>50.96% (53)</td>
<td>52.63% (10)</td>
<td>60% (6)</td>
<td>47.06% (8)</td>
<td>50.59% (43)</td>
</tr>
<tr>
<td>Age at PD onset, mean ± SDa</td>
<td>53.37 ± 12.31</td>
<td>54.58 ± 12.90</td>
<td>54.0 ± 12.32</td>
<td>55.0 ± 13.89</td>
<td>53.09 ± 12.23</td>
</tr>
<tr>
<td>LRRK2 mutation, % positive (n)</td>
<td>2.88% (3)</td>
<td>10.53% (2)</td>
<td>25% (2)</td>
<td>0% (0)</td>
<td>1.18% (1)</td>
</tr>
<tr>
<td>Family history of PDb</td>
<td>31.37% (32 of 102)</td>
<td>22.22% (4 of 18)</td>
<td>25% (2 of 8)</td>
<td>20% (2 of 10)</td>
<td>33.33% (28 of 84)</td>
</tr>
</tbody>
</table>

aAge onset unknown for 3 subjects.

bProband reported family history of Parkinson disease in first-, second-, or third-degree relatives; data not available for 3 subjects.
Familial 7q21.3 Microdeletion Involving Epsilon-Sarcoglycan Causing Myoclonus Dystonia, Cognitive Impairment, and Psychosis

The most common genetic cause of myoclonus dystonia is a heterozygous mutation or deletion in the gene epsilon-sarcoglycan (SGCE), which is present in 20%–80% of patients. The classic phenotype is early-onset (mean, 6 years) upper body myoclonus and dystonia to a lesser extent. Associated emotional disorders are common, and psychosis has been occasionally described. Although the majority of SGCE mutations can be detected using direct sequencing, large deletions of SGCE can cause myoclonus dystonia that require detection using assays that detect copy-number variants and gene dosage. We report an unusual family with a 0.17-Mb microdeletion resulting in 90% loss of SGCE whose members had myoclonus dystonia, cognitive impairment, and psychosis.

Case III:1 (Fig. 1) is a 17-year-old female who had mild language delay in early childhood. She walked at 18 months, but her gait was awkward, and she tripped excessively. Since her third year, she has experienced large-amplitude myoclonus of the arms and trunk that is intermittent and increases during stress and in social situations. She has cognitive impairment, with a full-scale IQ of 69, verbal IQ of 65, verbal comprehension IQ of 70, performance IQ of 78, and perceptual organization of 85 (WISC III). She has occasional panic attacks but refuses to medicate herself, yet maintains living independently. Case III:2, a 15-year-old female, also had mild developmental delay. She requires extra support at school but has never had formal psychometric testing. From the age of 2, she had awkward walking, with dystonic posturing of the feet exaggerated by stress. She also has intermittent myoclonic jerks of the upper limbs and trunk, although less than her sister. Case III:3, the father of the index cases, now 50 years of age, has never had cognitive impairment or movement disorders. From the age of 2, he has experienced large-amplitude myoclonus evident on examination on 2 separate examinations. Case III:2, a 15-year-old female, also had mild developmental delay. She requires extra support at school but has never had formal psychometric testing. From the age of 2, she had awkward walking, with dystonic posturing of the feet exaggerated by stress. She also has intermittent myoclonic jerks of the upper limbs and trunk, although less than her sister. Case II:3, the father of the index cases, now 50 years of age, has never had cognitive impairment or movement disorders. At age 38, he developed acute-onset paranoia that people were watching him, talking about him, and “out to get him.” He denied auditory hallucinations. He had religious preoccupations and was given a diagnosis of paranoid schizophrenia. He has taken risperidone since that time and has never returned to work, but remains in the family home. The extended family is notable for the high incidence of psychosis (Fig. 1). Case II:1, now age 54 years, was diagnosed with schizophrenia in his thirties, continues to have delusional beliefs, does not work, and is resident in a home for people with mental health problems. Case II:5, now age 47 years, presented with delusions, hallucinations, and self-harm and was diagnosed with schizophrenia in her thirties. She continues to take antipsychotics but lives independently. Case II:6, now age 46 years, was diagnosed with schizophrenia in her thirties but refused to medicate herself, yet maintains living independently. Using a Sureprint G3HFmm Comparative Genomic Hybridization (CGH) 2×400 K microarray with effective resolution of 0.06 Mb, a deletion was found on chromosome 7, band q21.3. The microdeletion had a minimum size of 0.17 Mb and extended from position 93.93 to 94.10 Mb. This deletion involves 2 genes only, CASD1 (whole gene deleted) and SGCE (90% deleted), and was found in both index cases (III:1 and III:2) and in their father (II:3). The CGH microarray was normal in the mother of the index cases.

This family represents a further example of paternally inherited myoclonus dystonia from large deletions of SGCE. Only assays that can detect alterations in gene dosage will detect these large mutations. The contiguous gene CASD1 was also deleted, but CASD1 has no known function at a molecular level, or in human disease. The movement disorder was surprisingly mild in the index cases. The more pressing concern for the family was the cognitive impairment in the index cases and the familial psychosis. The father, despite carrying the same deletion as his daughters, denied any history of movement disorder, but instead presented with a psychotic illness in his thirties. His family history is remarkable for the high incidence of psychosis in his siblings, although these extended family members were unavailable for SGCE testing. It is theoretically possible that this familial psychosis is due to another, unidentified gene. However, given that epsilon-sarcoglycan is a brain protein and that SGCE mutations can result in psychiatric disease (including psychosis), we suspect that this microdeletion may represent the genetic risk factor for psychosis in this family.

Acknowledgments: We thank Mr. Artur Darmanian (Cytogenetics, CHW) for his critical involvement in the microarray test procedure. We thank the family for consenting to this report.

Russell C. Dale, PhD, Julian J. Nasti, MBBS, Greg B. Peters, PhD

1Institute of Neuroscience and Muscle Research Children’s Hospital at Westmead
University of Sydney, Sydney, Australia; 2Nepean Hospital, University of Sydney
Sydney, Australia; 3Department of Cytogenetics Children’s Hospital at Westmead
University of Sydney, Sydney, Australia

References
Singular DYT6 Phenotypes in Association with New THAP1 Frameshift Mutations

DYT6 dystonia is an autosomal dominant disorder with incomplete penetrance (~60%) characterized by early-age onset (median, 13 years) and slight female predominance. The upper limb is a common site of onset, with progressive extension of the disease to other body parts. The cranial region is affected in almost two thirds of patients, and the functional repercussions of the disease are perceived by patients as mainly a result of disturbances in this region and particularly to the speech problems present in more than half of the patients; functional impairment is moderate overall (patients remain ambulatory). THAP1 gene mutations have now been identified in numerous DYT6 families. Here we describe 2 new THAP1 mutations identified in non-Amish patients with primary non-DYT1 dystonia.

Patients were selected among those followed in outpatient clinics by trained neurologists from the French Dystonia network. Eight index patients were recruited from Polish outpatient clinics through an international collaboration. A set of 178 independent index patients with primary non-DYT1 dystonia were included. Patients with a mean age at onset of 20.4 ± 16.7 years were diagnosed as having “generalized, segmental, or multifocal dystonia” (54% of patients), or “oromandibular or cervical dystonia” (21.3%). Moreover, as clinical expression of DYT6 has been redefined as “broad and overlapping with non-DYT6 dystonia subtypes,” we also included patients with “blepharospasm” (7.3%) or with “other focal dystonia” such as writer’s cramp (17.4%). Sixty-three percent were isolated cases, and autosomal dominant transmission with sometimes incomplete penetrance was observed in families. Informed consent and blood samples were collected and DNA extracted from peripheral lymphocytes according to standard procedures. Direct sequencing of the 3 THAP1 coding regions and their exon boundaries was carried out. In the group of “generalized, segmental, or multifocal dystonia,” we identified 2 novel THAP1 heterozygous mutations (c.377_378delCT deletion [p.Pro126ArgFsX2] in patient 1; c.514dupA insertion [p.Arg172LysFsX7] in patient 3) (Supplementary Figure 1). The same THAP1 deletion was identified in the dystonic sibling of patient 1 (patient 2). These new frameshift mutations result in the formation of premature STOP codons at positions 127 and 178.
respectively, and suggest, as previously reported, a loss-of-function mechanism by haploinsufficiency.

The clinical picture of these 3 patients (Table 1) fits with the clinical phenotype associated with THAP1 mutations, but some clinical aspects are singular. In patient 3, dystonia initially implicated the right upper limb at the age of 9, with progressive axial involvement; at 14 years of age, the right upper limb and the cervical region were clearly dystonic, with writer’s cramp and torticollis. The patient was not treated. At the age of 18 the patient reported spontaneous, complete remission (cervical and upper limb). This remission was transient, and after a free interval of 4 years, without any obvious triggering factor, dystonia rapidly recurred with right arm and cervical involvement. Afterward, dystonia did not spread to other body parts; upper limb dystonia remained moderate and stable, and disability was mainly due to cervical involvement. No worsening or remission has been reported since the age of 22, except for partial improvement after trihexiphenydyl treatment and botulinum toxin injections in the neck. Such transient improvement, or “honeymoon,” is not uncommon in other primary dystonias, particularly in cervical dystonia, but usually occurs within the first 5 years after onset. To our knowledge, such a honeymoon has never been observed in other known DYT6 patients.

Patient 1 is remarkable because of the lower limb onset of the disease at an early age, thus mimicking DYT1 dystonia. Nevertheless, upper limb onset is reported in more than half of DYT6 patients, and cranial onset occurs in one quarter of the cases (Table 1). In patients 1 and 2, who are siblings, dystonia became progressively generalized, with prominent cranial involvement, as described in almost half the DYT6 patients reported in the literature.

Although the 3 patients did not report any family history of motor disabilities or movement disorders (except for the sibling of patient 1), unfortunately, other family members could not be examined or tested for THAP1 mutations. Patient 3 was thus considered a sporadic case.

The occurrence of cognitive and psychiatric disorders is an area of uncertainty in rare genetic forms of dystonia. Standardized cognitive and psychiatric assessments were not performed in our 3 patients; they were all university graduates, and their past medical histories was uneventful for psychiatric disturbances. Paisan-Ruiz reported cognitive changes in 1 DYT6 patient. Cognitive or psychiatric functions among mutation carriers will need to be better analyzed.

In conclusion, THAP1 implication in primary dystonia is rare in non-Amish patients (about 1.5% of tested dystonic patients reported in the literature). The DYT6 phenotype overlaps with that of other forms of primary early-onset dystonia, especially DYT1 dystonia. Good candidates for THAP1 screening might be patients with onset in childhood or during adolescence who present cervicocranial and upper limb involvement or generalized dystonia and cranial involvement.

Acknowledgments: We thank all patients and family members for participation in this study.

Note that during the reviewing process, several new THAP1 mutations were reported (Zittel et al, Groen et al., Sohn et al, Cheng et al, and De Carvalho et al).

Arnaud Blanchard, MS, Agathe Roubertie, MD, PhD, Marion Simonetta-Moreau, MD, PhD, Vuthy Ea, MS, Coline Coquart, Melissa Y. Frederic, PhD.
**LETTERS: NEW OBSERVATIONS**

Pantothenate Kinase–Associated Neurodegeneration: Clinical Description of 10 Patients and Identification of New Mutations

Pantothenate kinase–associated neurodegeneration (PKAN) is a rare autosomal recessive neurodegenerative disorder of childhood onset, characterized by progressive dystonia and iron accumulation in the brain, mainly in the globus pallidus and the pars reticulata of the substantia nigra. Patients have mutations in the gene encoding pantothenate kinase 2 (PANK2), a key regulatory enzyme in the biosynthesis of coenzyme A.

We ascertained 10 patients from 3 unrelated Algerian families between 1997 and 2008; all were examined at different stages of the disease and presented with early-onset, typical, 3–5 and rarely described clinical PKAN features (Table 1 and Supplementary Fig. 1). Hyperactivity (Video) and attention deficit rarely described in previous series but observed in most of our patients were inaugural signs of the disease, as demonstrated by the absence of any other clinical signs in patient F2P4 at the age of 3 years. Pigmentary retinopathy, present in all our patients, was also considered as an early sign because it was already detectable in the neurologically asymptomatic patient (F2P4). The phenotype thereafter extended with abnormal falls

**References**


Additional Supporting Information may be found in the online version of this article.

*Correspondence to: Meriem Tazir, Department of Neurology, CHU Mustapha Bacha and Laboratoire de Neurosciences, Université d’Alger, Algérie; meriem.tazir@sante.dz*

**Relevant conflicts of interest/financial disclosures:** Nothing to report. This work received support from the Ministère de la Santé, de la Population et de la Réforme Hospitalière (Algeria), the Ministère de l’Enseignement Supérieur et de la Recherche Scientifique (Algeria), the Agence Nationale de la Recherche (France, to A.D. and G.S.), the Association Française contre les Myopathies (APM, France; to H.A.) and the Verum Foundation (Germany; to A.B.).

Published online 25 March 2011 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.23648
## Table 1. Clinical and molecular results

<table>
<thead>
<tr>
<th>Family/patient</th>
<th>F1P1</th>
<th>F1P2</th>
<th>F2P1</th>
<th>F2P2</th>
<th>F3P1</th>
<th>F3P2</th>
<th>F3P3</th>
<th>F3P4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sex</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>M</td>
<td>F</td>
<td>F</td>
<td>M</td>
</tr>
<tr>
<td>Age at onset (y)</td>
<td>3</td>
<td>3</td>
<td>5</td>
<td>8</td>
<td>3</td>
<td>3</td>
<td>6</td>
<td>7</td>
</tr>
<tr>
<td>Age at last examination (y) or age at death</td>
<td>12 (death)</td>
<td>13 (death)</td>
<td>22</td>
<td>14 (death)</td>
<td>15</td>
<td>4</td>
<td>12</td>
<td>26</td>
</tr>
<tr>
<td>Disease duration (y)</td>
<td>9</td>
<td>10</td>
<td>17</td>
<td>6</td>
<td>12</td>
<td>1</td>
<td>6</td>
<td>19</td>
</tr>
<tr>
<td>Signs at onset other than gait or postural difficulties</td>
<td>Ataxia, frequent falls, hyperactivity, attention deficit, language delay</td>
<td>Ataxia, frequent falls, hyperactivity, attention deficit, language delay</td>
<td>Frequent falls</td>
<td>Hyperactivity, attention deficit, retrocollis, difficulty in writing</td>
<td>Hyperactivity, attention deficit, language delay</td>
<td>Hyperactivity, frequent falls, hyperactivity, dysarthria</td>
<td>Toe walking</td>
<td>Hyperactivity, aggressivity</td>
</tr>
<tr>
<td>Oromandibular-facial dystonia</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Cranial, cervical dystonia</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Dysarthria/age at loss of speech</td>
<td>+1/10</td>
<td>+1/10</td>
<td>+/15</td>
<td>+/12</td>
<td>+</td>
<td>+/14</td>
<td>+/8</td>
<td>+/15</td>
</tr>
<tr>
<td>Generalized dystonia/age (y)</td>
<td>+/10</td>
<td>+/10</td>
<td>+/15</td>
<td>+</td>
<td>+/14</td>
<td>+/8</td>
<td>+/15</td>
<td>+</td>
</tr>
<tr>
<td>Pyramidal signs</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Loss of ambulation/age (y)</td>
<td>+/10</td>
<td>+/11</td>
<td>+/10</td>
<td>+/12</td>
<td>+/12</td>
<td>+/10</td>
<td>+/14</td>
<td>+/16</td>
</tr>
<tr>
<td>Painful paroxystic rigidity/age (y)</td>
<td>+/12 with severe axial dystonia</td>
<td>+/12 with severe axial dystonia</td>
<td>–</td>
<td>–</td>
<td>++/+15</td>
<td>–</td>
<td>++/11</td>
<td>–</td>
</tr>
<tr>
<td>Swallowing difficulties</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Pigmentary retinopathy/age (y)</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Cognitive decline</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
<td>Moderate</td>
<td>–</td>
<td>Moderate</td>
<td>–</td>
<td>Moderate</td>
</tr>
<tr>
<td>Acanthocytosis</td>
<td>ND</td>
<td>ND</td>
<td>Rare cells</td>
<td>ND</td>
<td>Rare cells</td>
<td>–</td>
<td>Rare cells</td>
<td>–</td>
</tr>
<tr>
<td>Brain MRI</td>
<td>ND</td>
<td>ND</td>
<td>Eye of the tiger sign</td>
<td>ND</td>
<td>Eye of the tiger sign</td>
<td>–</td>
<td>Eye of the tiger sign</td>
<td>–</td>
</tr>
<tr>
<td>DNA mutation</td>
<td>c.846_847delAG</td>
<td>c.846_847delAG</td>
<td>c.1171_1174delATTG</td>
<td>c.1171_1174delATTG</td>
<td>c.1171_1174delATTG</td>
<td>c.1171_1174delATTG</td>
<td>c.1171_1174delATTG</td>
<td>c.457A&gt;T (hm)</td>
</tr>
</tbody>
</table>

hm, Homozygous; ht, heterozygous; ND, not done; + = present; – = absent; ++ = severe.
and gait or postural difficulties, followed by the typical PKAN signs (Video and Supplementary Fig. 2). Loss of speech was observed at a mean age of 9.5 ± 1.4 years. Progression was rapid in the first decade, with loss of independent ambulation at a mean age of 11.7 ± 1.9 years with generalized dystonia. Life expectancy differed greatly between patients, as some patients died during early adolescence, at 17 (F3P3) and 14 (F2P2), and others with the same mutation were still alive at 26 (F3P2) and 22 (F2P1).

The T2-weighted brain MRI showed the “eye of the tiger” sign, the specific pattern of hyperintensity within the hypointense medio-basal globus pallidus. Interestingly, in the asymptomatic patient F2P4, there was predominantly a hyperintensity within the globus pallidus (Supplementary Fig. 3).

Recently, 1 patient (F2P1) with oromandibular dystonia, difficulty with opening her jaw, and consequently a failure to thrive, was successfully treated with botulinum toxin, leading to better feeding.

Direct sequencing and MLPA analysis of PANK2 in 1 affected patient from each of the 3 families identified 2 known homozygous truncating PANK2 mutations (c.846_847delAG/p.S282fsX3 in exon 3 and c.1171_1174dupATTG/p.G392DfsX11 in exon 5) that were shown to segregate with the disease in all patients in families 1 and 2, respectively. Interestingly, in 1 branch of family 3, all the patients were double homozygous for 2 missense variants (c.457A>T/p.I153F and c.519C>T/p.H173Q occurring in exon 2). These variants were absent in 898 control chromosomes and were highly conserved in at least 10 species (Supplementary Fig. 1). It has been previously shown that truncating mutations are associated with an earlier age at onset compared with missense variants. In contrast, our 3 double homozygous patients with missense mutations had similar ages at onset as homozygous patients, with loss of function mutations, suggesting that both missense variants are deleterious, leading to a very low level of enzymatic activity. Interestingly, the single patient (F3P1) of the other branch of this family had a particular genotype that he inherited from his mother, the truncating mutation (c.1171_1174dupATTG/p.G392DfsX11) identified in family 2, and received from his father, the 2 missense variants in cis position identified in the other branch of family 3. This is the first description of a triple compound heterozygous patient in PKAN, whereas this has been reported in other diseases. In this case, the truncating mutation was associated with single flanking haplotypes (Supplementary Fig. 1), suggesting a common ancestor.

In conclusion, we report 3 new PANK2 families (10 patients) and 2 novel missense mutations cosegregating in the cis position in 1 kindred. Although the main typical signs of the disease associated with an early onset were present in all patients, as in previously reported cases, this report confirms the broad phenotypic spectrum of PKAN and differences in survival, even among siblings with identical mutations. Other genetic or epigenetic factors could play a role in this phenotypic heterogeneity.

Video Legend—Patient F2P3. Patient F2P3 presents with severe axial and upper limb dystonic movements with hyperextension of the neck and head together with painful laryngeal spasm and hypersalivation.

Video Legend—Patient F2P1. Patient F2P1 presents with axial and dystonic movements at all limbs with oromandibular dystonia.

Video Legend—Case F2P4. Case F2P4 has normal walk but instability on the half-turn.

Salima Assami, MD,1 Hamid Azzedine, PhD,2,3 Sonia Nouioua, MD,1 Emeline Mundwiller, BS2,3 Souilaiman Mahoui, MD,1 Samira Makri, MD,4 Meriam Djemai, MD,1 Djamel Grid, MD,6 Alexis Brice, MD, PhD,2,3,7 Tarik Hamadouche, PhD,8 Giovanni Stevanin, PhD,2,3,7,9 Meriem Tazir, MD1

1Department of Neurology, CHU Mustapha Bacha and Laboratoire de Neurosciences, Université d’Alger, Algérie, Algeria; 2INSERM, U975 (formerly U679), Paris, France; 3UMPC Univ. Paris 6 UMR_S975, CNRS 7225, Centre de Recherche de l’Institut du Cerveau et de la Moelle épinière, Hôpital Pitité-Salpêtrière, Paris, France; 4EHS Ali Aït Idir; 5Service de Neurologie, CHU Bab el Oued, Algiers, Algeria; 6Généthon, Paris, France; 7APHP, Department of Genetics, and Cytogenetics, Hôpital Pitité-Salpêtrière, Paris, France; 8Laboratoire de Biologie Moléculaire, Université Mhamed Bougara, Boumerdes, Algeria; 9École Pratique des Hautes Etudes, Paris, France

References
Behavioral Factors Influence the Phenotype of Musician’s Dystonia

Focal dystonia in musicians (musician’s dystonia, MD) is a task-specific movement disorder that presents with loss of voluntary motor control when a musician is playing the instrument.\(^1,2\) The pathophysiology is still not fully understood.\(^3\) Recently, predilections of certain instruments to affect certain body parts were reported.\(^4\) Pianists and guitarists are affected predominantly in the right hand, bowed string players, in contrast, in the left hand. These predilections were shown to be related to the technical burden and spatiotemporal constraints required by the nature of the instrument.\(^4,5\) Two questions remain unanswered. First, may extramuscular workload, that is, intense usage of the dominant hand in daily-life activities, additionally affect the localization of MD? And, second, does predilection relate solely to the localization of dystonic movements, or does the nature of highly trained movements influence the type of dystonia? We hypothesized that (1) workload of daily activities given by handedness may additionally influence the localization of MD and (2) the nature of movements required by the respective instrument may additionally influence the dystonic movement patterns of MD. Focal, task-specific tremor (FT) is rare and sometimes the only symptom of MD. Although an increased ratio of patients with FT was seen among bowed string players,\(^6\) FT has not been reliably associated with specific movement patterns of certain instruments. According to our second hypothesis, we expected FT to be overrepresented in bowed string players because of the repetitive nature of similar movements in this group (vibrato movements in the left hand, repetitive bowing movements in the right hand) in contrast with all other instrument groups.

For the study, patients were recruited from the outpatient clinic of the Hanover Institute of Music Physiology and Musicians’ Medicine. All patients diagnosed with MD from 1994 until 2007 were included (n = 591). The following data were collected from patients’ charts: (1) instrument played, (2) side of the affected hand/arm, and (3) self-declared handedness. None of the patients showed clinical evidence of essential tremor. To detect disproportionate handedness distributions in patients with unilateral hand dystonia (MHD; n = 362), we used a 1-way chi-square test contrasting the distribution of handedness in patients with right-sided MHD versus left-sided MHD. To analyze the distribution of tremor versus non-tremor dystonic symptoms in each of the 6 instrumental groups (keyboard, bowed string, plucked string, woodwind, brass, and percussion), we applied Fisher’s exact tests. Each instrument group was contrasted with all other groups, resulting in one 2-by-2 table per instrument group. P < .05 (2-tailed) was considered statistically significant. For multiple Fisher’s exact tests, Bonferroni correction was applied (corrected α = 0.0083).

Handedness distribution in patients with right- and left-sided MHD was significantly different (\(\chi^2_{(1)} = 4.07, P < .05\)): The ratio of right-handers was higher in patients with right-sided MHD (92.4%; left-handers, 7.6%) compared with those with left-sided MHD (85.7%; left-handers, 14.3%). Right-sided MHD was more frequent than left-sided in keyboard and plucked string players, with the converse pattern in bowed string players (each, P < .05; this will be reported elsewhere in detail). However, handedness was not associated with instrument groups (keyboard and plucked string players vs bowed string players, \(\chi^2_{(1)} = 0.03, P = .87\)). Among the 591 patients, 18 (3.0%) suffered from FT, 571 (96.6%) showed typical MD symptoms of cramping, and 2 (0.3%, excluded from the analysis) had both symptoms. The ratio of patients with FT was higher in bowed string players compared with all other instrument groups (9.9% vs 2.0%, \(P = .001\)). FT in bowed string players occurred only on the right side (2 patients had arm FT, 6 had hand FT). No significant differences were seen for the remaining instrument groups (each, P > .018).

Findings showed that, first, extramuscular burdens of daily-life activities reflected by handedness were related to localization of MHD. Moreover, second, the nature of movements required by the respective instrument was related to the dystonic movement patterns of MD, as seen in the increased occurrence of FT in bowed string players. It has been discussed that both environmental and genetic factors are important in the development of focal dystonia.\(^3,7\) Genetic studies suggest that vulnerability to MD is subject to hereditary transmission. Based on previous epidemiological studies and our results, we suggest that phenotypic occurrence of MD is more heavily influenced by environmental and behavioral factors than previously assumed. As a limitation, it cannot be excluded that there are genetic factors that might determine both handedness and vulnerability to developing MHD in the dominant hand.

Acknowledgments: We thank Aurélie Hofmann for assistance with data acquisition.

Volker Baur, MSc,\(^1,2\) Hans-Christian Jabusch, MD,\(^3\) Eckart Altenmüller, MD.\(^1,7\)

\(^1\)Institute of Music Physiology and Musicians’ Medicine, University of Music and Drama, Hanover, Germany; \(^2\)Division Neuropsychology, Institute of Psychology, University of Zurich, Zurich, Switzerland; \(^3\)Institute of Musicians’ Medicine, University of Music Carl Maria von Weber, Dresden, Germany
Racial Differences May Influence the Role of Cholecystokinin Polymorphisms in Parkinson’s Disease Hallucinations

Psychosis is a frequently troublesome complication in Parkinson’s disease (PD). Various genetic polymorphisms affecting dopamine have been reported as risk factors for PD-related complications such as dyskinesias and hallucinations. Cholecystokinin (CCK) has been implicated in psychiatric disorders including schizophrenia and panic disorder, and CCK and receptor (CCKAR and CCKBR) gene polymorphisms have been investigated in PD hallucinations. CCK–dopamine interactions may contribute to the neurobiology of psychiatric disorders, as CCK colocalizes with dopamine in mesolimbic neurons, including those in the nucleus accumbens and amygdala, and modulates dopaminergic release. In Asian PD patients, an increased hallucination risk was associated with CCK and CCKAR gene polymorphisms. Because genetic polymorphisms vary across racial groups, we aimed to replicate these findings in white PD patients with chronic hallucinations compared with those who never hallucinated.

We conducted a case–control study at the Rush University Movement Disorders clinic, examining 88 pairs of white PD patients with and without chronic hallucinations, matched for age within 3 years, disease duration within 5 years, and dopaminergic medications (levodopa, agonist, or both). Cases had hallucinated at least 3 times weekly for the past 2 months and had not experienced hallucinations before dopaminergic treatment, whereas controls had never hallucinated. Only controls with at least 1 year of continual clinical follow-up were included. Mini–Mental State Examination (MMSE), Unified Parkinson Disease Rating Scale (UPDRS) motor section, and Hoehn and Yahr staging were also administered. Only white, non-Hispanic, non-Latino patients participated. The Rush University Institutional Review Board approved this research.

Genomic DNA from coded samples was analyzed for CCK-45C/T, CCKAR 779T/C, and CCKBR 1550G/A polymorphisms by polymerase chain reaction. We specifically examined polymorphisms identified in the Asian studies, including the promoter region CCK -45 CT polymorphism, which may influence CCK gene transcription based on its Sp1 cis-binding element location. Based on prior studies, our sample size of 88 pairs afforded >90% power to detect a difference of 22% between cases and controls, assuming a CCK-T allele frequency of 14% in white PD controls. Only controls with at least 1 year of continual clinical follow-up were included. Mini–Mental State Examination (MMSE), Unified Parkinson Disease Rating Scale (UPDRS) motor section, and Hoehn and Yahr staging were also administered. Only white, non-Hispanic, non-Latino patients participated. The Rush University Institutional Review Board approved this research.

Genomic DNA from coded samples was analyzed for CCK-45C/T, CCKAR 779T/C, and CCKBR 1550G/A polymorphisms by polymerase chain reaction. We specifically examined polymorphisms identified in the Asian studies, including the promoter region CCK -45 CT polymorphism, which may influence CCK gene transcription based on its Sp1 cis-binding element location. Based on prior studies, our sample size of 88 pairs afforded >90% power to detect a difference of 22% between cases and controls, assuming a CCK-T allele frequency of 14% in white PD controls. Only controls with at least 1 year of continual clinical follow-up were included. Mini–Mental State Examination (MMSE), Unified Parkinson Disease Rating Scale (UPDRS) motor section, and Hoehn and Yahr staging were also administered. Only white, non-Hispanic, non-Latino patients participated. The Rush University Institutional Review Board approved this research.

Genomic DNA from coded samples was analyzed for CCK-45C/T, CCKAR 779T/C, and CCKBR 1550G/A polymorphisms by polymerase chain reaction. We specifically examined polymorphisms identified in the Asian studies, including the promoter region CCK -45 CT polymorphism, which may influence CCK gene transcription based on its Sp1 cis-binding element location. Based on prior studies, our sample size of 88 pairs afforded >90% power to detect a difference of 22% between cases and controls, assuming a CCK-T allele frequency of 14% in white PD controls. Only controls with at least 1 year of continual clinical follow-up were included. Mini–Mental State Examination (MMSE), Unified Parkinson Disease Rating Scale (UPDRS) motor section, and Hoehn and Yahr staging were also administered. Only white, non-Hispanic, non-Latino patients participated. The Rush University Institutional Review Board approved this research.

Genomic DNA from coded samples was analyzed for CCK-45C/T, CCKAR 779T/C, and CCKBR 1550G/A polymorphisms by polymerase chain reaction. We specifically examined polymorphisms identified in the Asian studies, including the promoter region CCK -45 CT polymorphism, which may influence CCK gene transcription based on its Sp1 cis-binding element location. Based on prior studies, our sample size of 88 pairs afforded >90% power to detect a difference of 22% between cases and controls, assuming a CCK-T allele frequency of 14% in white PD controls. Only controls with at least 1 year of continual clinical follow-up were included. Mini–Mental State Examination (MMSE), Unified Parkinson Disease Rating Scale (UPDRS) motor section, and Hoehn and Yahr staging were also administered. Only white, non-Hispanic, non-Latino patients participated. The Rush University Institutional Review Board approved this research.

Genomic DNA from coded samples was analyzed for CCK-45C/T, CCKAR 779T/C, and CCKBR 1550G/A polymorphisms by polymerase chain reaction. We specifically examined polymorphisms identified in the Asian studies, including the promoter region CCK -45 CT polymorphism, which may influence CCK gene transcription based on its Sp1 cis-binding element location. Based on prior studies, our sample size of 88 pairs afforded >90% power to detect a difference of 22% between cases and controls, assuming a CCK-T allele frequency of 14% in white PD controls. Only controls with at least 1 year of continual clinical follow-up were included. Mini–Mental State Examination (MMSE), Unified Parkinson Disease Rating Scale (UPDRS) motor section, and Hoehn and Yahr staging were also administered. Only white, non-Hispanic, non-Latino patients participated. The Rush University Institutional Review Board approved this research.

Genomic DNA from coded samples was analyzed for CCK-45C/T, CCKAR 779T/C, and CCKBR 1550G/A polymorphisms by polymerase chain reaction. We specifically examined polymorphisms identified in the Asian studies, including the promoter region CCK -45 CT polymorphism, which may influence CCK gene transcription based on its Sp1 cis-binding element location. Based on prior studies, our sample size of 88 pairs afforded >90% power to detect a difference of 22% between cases and controls, assuming a CCK-T allele frequency of 14% in white PD controls. Only controls with at least 1 year of continual clinical follow-up were included. Mini–Mental State Examination (MMSE), Unified Parkinson Disease Rating Scale (UPDRS) motor section, and Hoehn and Yahr staging were also administered. Only white, non-Hispanic, non-Latino patients participated. The Rush University Institutional Review Board approved this research.
Mean clinical follow-up for nonhallucinating controls was 3.79 years (SD, 3.22 years), maximum 15 years.

CCK, CCKAR, and CCKBR genotype frequencies were in Hardy–Weinberg equilibrium. For CCK, CCKAR, and CCKBR, there were no significant differences in genotype distributions or allele frequencies between hallucinators or non-hallucinators (Table 1). In fact, the CCK-T allele was modestly represented in both groups (16%, hallucinators; 14%, non-hallucinators; p = .55). We also did not detect increased hallucinatory risk with combined CCK-T and CCKAR-C alleles.

Our matched case–control study did not replicate the association between CCK or CCKAR polymorphisms and increased hallucination risk previously found in Japanese and Chinese PD patients. In both Asian studies, the CCK-T allele frequency in PD hallucinators was about 40%, a finding detected in smaller hallucinator samples (n = 23 and n = 45, respectively). In contrast, the overall CCK-T allele frequency was 15% in our white PD cohort, without significant differences between hallucinators and nonhallucinators. Our CCK-T allele frequency, however, was similar to studies in American white populations (14%), but lower than frequencies reported in Asian populations (32%, Japanese; 33%, Chinese). Our study was powered to detect a contribution of the CCK-T allele to hallucination status that would account for a similar magnitude of risk, as proposed in the Asian studies, despite the lower population CCK-T allele frequency in whites. Thus, the CCK-related polymorphisms studied appear to differentially affect hallucination risk in PD across different racial groups. Genetic polymorphisms as risk factors for disease-related complications such as hallucinations should be interpreted within the context of racial and ethnic diversity.

Our methodological strengths include a well-matched study population, diagnoses by movement disorder specialists, and follow-up of nonhallucinating patients to ensure group classification. Limitations include the tertiary-care referral pattern, study of only gene polymorphisms showing group classification. Limitations include the tertiary-care referral pattern, study of only gene polymorphisms showing prior associations, and that even with rigorous follow-up of nonhallucinators, we cannot confirm that they will never hallucinate.

Although particular CCK and CCK receptor gene polymorphisms may increase hallucination risk in Asian PD patients, the lack of differences in allele frequencies in our cohort suggests that these polymorphisms are not substantial contributors to the psychosis risk in white PD patients.

Jennifer G. Goldman, MD, MS,1*
Darcy Marr, MS,2 Lili Zhou, MD,3
Bichun Ouyang, PhD,4 Sue E. Leurgans, PhD,1,4
Elizabeth Berry-Kravis, MD, PhD1,3,5
and Christopher G. Goetz, MD4

1Department of Neurological Sciences, Rush University Medical Center, Chicago, Illinois, USA;
2University of British Columbia, Vancouver, British Columbia, Canada;
3Department of Pediatrics, Rush University Medical Center, Chicago, Illinois, USA;
4Department of Preventive Medicine, Rush University Medical Center, Chicago, Illinois, USA; and
5Department of Biochemistry, Rush University Medical Center, Chicago, Illinois, USA.

References


“Silly Walks” in Parkinson’s Disease: Unusual Presentation of Dopaminergic-Induced Dyskinesias

It is widely recognized that dopaminergic-induced dyskinesias can interfere with gait in advanced Parkinson’s disease (PD). However, levodopa-induced dyskinesias can sometimes take bizarre forms and may easily be mistaken for psychogenic movement disorders. Here, we present 4 PD patients with strikingly similar bizarre gait related to the effects of levodopa.

Patient 1 developed clumsiness of the left leg and hand at age 44. He was diagnosed with PD, and levodopa treatment was initiated. Six years later, a psychogenic cause was suspected because of bizarre leg movements interfering with stability and gait. We discovered that these dyskinesias mainly occurred at the beginning and end of each levodopa dose effect (Video Patient 1, Segments 1 and 2). In-between these effects (Video Patient 1, Segments 1 and 2). In-between these
periods, the patient experienced motor improvement (Video Patient 1, Segment 3).

Patient 2 developed hypokinesia and rigidity in the left arm at age 38. Levodopa was initiated, with good effect on motor function. Three years later, he complained of a short and unpredictable effect of levodopa, usually with a period of immobility and abnormal leg movements preceding the advent of the next dose effect (Video Patient 2, Segment 1). After overnight withdrawal of all medication, the patient showed generalized bradykinesia plus dystonia of the right foot (Video Patient 2, Segment 2). Thirty-five minutes after a levodopa dose, ballistic kicking and stamping appeared in the left leg on walking, along with persistent dystonic posturing of the left arm (Video Patient 2, Segment 3). In his full “on” state, the patient showed only mild choreodystonia not interfering with gait (Video Patient 2, Segment 4).

Patient 3 was diagnosed with PD beginning in his left arm at age 35. He started levodopa at age 36 with a good response. At age 41 he developed motor fluctuations and dyskinesias. During the “on” phase, he exhibited a striking, stereotyped kicking gait (Video Patient 3, Segment 1). When “off,” he was slow, with marked difficulty walking (Video Patient 3, Segment 2). Bilateral deep brain stimulation of the subthalamic nucleus (DBS STN) improved his parkinsonism and allowed reduction of his medications. He no longer exhibits this gait pattern.

Patient 4 developed PD at the age of 39. He responded well to dopaminergic medication, but after 4 years he developed wearing-off and dopaminergic-induced dyskinesias. In his best “on” phase, the patient shows violent choreatic dyskinesias involving the trunk, arms, and legs (Video Patient 4, Segment 1). In the practically defined “off” state, the patient’s gait is clearly bradykinetic, with small, slow, and shuffling steps (Video Patient 4, Segment 2). The patient subsequently received bilateral DBS STN, with substantial improvement of dyskinesias and gait.

There are several common elements to these case presentations. The first is the bizarre yet fairly stereotyped gait patterns. When videos of these patients were presented at conferences to experienced movement disorder specialists, the gait was generally thought to be psychogenic and reminiscent of the gait shown in Monty Python’s classic TV sketch “The Ministry of Silly Walks” (http://www.youtube.com/watch?v=9ZLBugJE6Hy). The gait we present here indeed looks bizarre, but it is also remarkably stereotyped across patients seen in 4 movement disorders clinics. Recurring characteristics include the stepping with kicks, high knee elevations, and ballistic “stamping” of 1 lower limb, generally on the side first affected by PD. In addition, dystonic postures of the contralateral foot and ipsilateral arm were seen in 2 patients, and dancing movements with hops and pelvis rotations were seen in 1 case.

An additional shared feature is that all are male patients whose PD began before the age of 45. In keeping with known experiences with such young-onset patients, they all developed early motor fluctuations and dyskinesias, starting only several years after the initiation of dopaminergic treatment.

Another important element was the timing of these abnormal movements in relation to the intake and clinical efficacy of dopaminergic medication. The first 2 patients clearly had a diphasic pattern: dyskinesias developed shortly following a levodopa dose, at the beginning of the therapeutic effect. When the levodopa effect increased further to reach a full “on” state, the dyskinesias largely disappeared, and gait improved considerably, consistent with previous descriptions of biphasic levodopa-induced dyskinesias that mainly affect subjects with early-onset PD and that are characterized by a stereotypic pattern, with a dystonic or ballistic form, and a violent expression. The predominance in the most affected leg corresponds to the observation that dyskinesias start and predominate in the leg contralateral to where dopaminergic denervation in the dorsal putamen is greatest. Optimizing dopaminergic therapy or DBS can be helpful in these patients, as was also demonstrated here.

Most importantly, the bizarre gait pattern should not be misdiagnosed as a psychogenic movement disorder, even if voluntary movements are sometimes superimposed as a compensation for the dyskinesias interfering with gait (possibly in patient 4). Another possibility is embellishment that, although not widely recognized, may occur as a superimposed movement abnormality in patients with otherwise genuine PD. Showing a similar case (#17), Hayes et al. appropriately warned about the danger of labeling a bizarre gait as psychogenic just on the basis that it is unlike anything that has been seen before.

Legends to the Video

Video Patient 1, Segment 1. When first seen by us, the patient presented with ballistic leg movements occurring at the beginning and at the end of each levodopa dose effect.

Video Patient 1, Segment 2. Twenty-five minutes after the levodopa dose, prominent rhythmic elevations of the left lower limb developed, interfering with walking and persisting when standing.

Video Patient 1, Segment 3. In the “on” state 1 hour after the levodopa dose, the patient showed only moderate choreo-dystonic movements not interfering with balance and gait.

Video Patient 2, Segment 1. On the first visit, ballistic stamping of the left leg markedly interfered with the patient’s gait.

Video Patient 2, Segment 2. After an overnight withdrawal of all dopaminergic medication, a generalized bradykinesia and dystonic arching of the right sole is seen.

Video Patient 2, Segment 3. Thirty-five minutes after levodopa/carbidopa 100/25 mg, involuntary movements appear on the lower limbs, with left leg kicking on walking, soon followed by ballistic leg stamping, along with persistent dystonic posturing of the patient’s left arm.

Video Patient 2, Segment 4. Fifty minutes after the levodopa dose, the patient is in the “on” state, with mild choreodystonia not markedly interfering with gait.

Video Patient 3, Segment 1. Striking, stereotyped kicking gait in the “on” state.

Video Patient 3, Segment 2. When “off” levodopa, the patient is slow and has marked difficulty walking.

Video Patient 4, Segment 1. In the patient’s best “on” phase, about 1 hour after intake of 187.5 mg of levodopa and 8 mg of ropinirole, his walking is severely hampered by violent choreatic dyskinesias involving the trunk, arms, and legs.
LETTERS: NEW OBSERVATIONS

Video Patient 4, Segment 2. In the “off” state, more than 12 hours after intake of the last dose of medication, the patient’s gait is clearly hypokinetic, with small, slow, and shuffling steps.

Evžen Růžička, MD, DSc,1,4 Kateřina Zárubová, MD,2 John G. Nutt, MD,1 and Bastiaan R. Bloem, MD, PhD5

1Department of Neurology and Centre of Clinical Neuroscience, First Faculty of Medicine and General University Hospital, Charles University in Prague, Prague, Czech Republic; 2Department of Neurology, Second Faculty of Medicine and University Hospital Motol, Charles University in Prague, Prague, Czech Republic; 3Department of Neurology, Oregon Health & Science University, Portland, Oregon, USA; and 4Department of Neurology and Parkinson Centre Nijmegen, Donders Institute for Brain, Cognition and Behaviour, Radboud University Nijmegen Medical Centre, Nijmegen, The Netherlands

References


Immediate Versus Delayed Electrical Stimulation Boosts Botulinum Toxin Effect: A Pilot Study

Electrical stimulation (ES) is reported to enhance the effect of botulinum toxin type A (BTX-A), but there is disagreement on the best ES protocol (time of administration, rate, duration).1–5 We carried out a pilot study aimed at comparing the efficacy of a single ES session of the injected muscles immediately after BTX-A administration versus repeated ES sessions beginning the day after inoculation.

Patients were recruited in the Neurorehabilitation Unit of the University Hospital of Verona, Italy. Inclusion criteria were first unilateral stroke, between 6 and 18 months after stroke, flexed elbow with spasticity of biceps brachii (BB) graded at least 2 (range, 0–5) on the Modified Ashworth Scale (MAS), and last BTX-A injection or any rehabilitative treatment at least 6 months prior to recruitment. Exclusion criteria were fixed contractures or bony deformities of the affected arm, previous treatment of arm spasticity with neurolytic or surgical procedures, and other neurological or orthopedic conditions involving the affected arm. Concentric needle electromyography was used to rule out patients with active denervation. Patients gave their consent for participation in the study, which was approved by the local Ethics Committee.

BTX-A (Botox; Allergan, Irvine, CA) 100 IU diluted with 2 mL of saline 0.9% was injected into the BB and the abductor digiti minimi (ADM) muscles of the affected arm. ADM was chosen because it offers a simple neurophysiologic marker of neuromuscular blockade and would have caused a very small disadvantage in the case of complete blockade. The BTX-A dose was 80 U for the BB and 15 U for the ADM in each patient. After injection, patients were randomized into 2 groups. All patients received ES of the injected muscles (rectangular current pulses, 4 Hz, 0.2 ms, intensity adjusted to elicit visible muscle contraction). Group A received ES of the injected muscles for 60 minutes immediately after BTX-A administration. Group B received ES for 30 minutes a day for 3 consecutive days, beginning the day after injection. None of the patients underwent any other treatment for spasticity during the study period.

All patients were evaluated immediately before (T0) and 4 weeks after (T1) BTX-A injection by the same examiner, who was blinded to the ES procedure they had received. Outcome measures were BB spasticity measured with the MAS and ADM compound muscle action potential (CMAP) amplitude. A decreased CMAP amplitude is considered a valid neurophysiologic quantification of toxin-induced neuromuscular blockade.6

The CMAP was recorded from the ADM muscle by supramaximal ulnar nerve stimulation at the wrist using disposable Ag/AgCl surface electrodes with belly-tendon montage. An infrared lamp was used to maintain hand skin temperature > 31°C during the recording. The position of the electrodes at T0 was recorded, and the electrodes were put in the same position at T1.

Differences between groups in the outcome measures were evaluated with the Mann–Whitney test, whereas differences between single variables in each group were evaluated with the Wilcoxon test at T1 versus T0. The significance level was P < .05.

Twenty-four patients (15 men; mean age, 63.7 years; 18 ischemic/6 hemorrhagic stroke; 15 right/9 left hemiplegia) were recruited from among 47 subjects with spastic

-----------------------------------------------------------------------------------------------------------------------------

*Correspondence to: Nicola Smania, Neuromotor and Cognitive Rehabilitation Research Center, Department of Neurological, Neuropsychological, Morphological and Movement Sciences, University of Verona, Italy; nicola.smania@univr.it

Relevant conflicts of interest/financial disclosures: Nothing to report.

Full financial disclosures and author roles may be found in the online version of this article.

Published online 29 April 2011 in Wiley Online Library (wileyonlinelibrary.com). DOI: 10.1002/mds.23678
hemiparesis consecutively evaluated from March 2009 to January 2010. None of the patients showed evidence of active denervation. No significant difference was found between the 2 groups in the clinical variables at baseline. Group A showed significantly lower MAS scores and better CMAP reductions than group B at T1 (Table 1).

BTX-A is rapidly internalized by high-affinity receptor-mediated endocytosis, which mainly occurs in a few minutes, and its translocation process occurs between 15 and 40 minutes after toxin exposure.6 Our results support greater chemodenervation, consistent with increased internalization of the toxin when ES is performed during the uptake process. Limitations of this study are the small sample size and the absence of a group treated only with BTX-A.

Previous findings about the effectiveness of long-term delayed ES protocols in enhancing BTX-A effect may be explained as follows: (1) several authors did not clearly state the time between injection and ES, and probably some of them started ES early after inoculation4,5; (2) some ES protocols stimulated also antagonist muscles1,3 probably involving other mechanisms (see reciprocal inhibition); and (3) ES may reduce spasticity by itself.7

Acknowledgments: We thank Prof. Cesare Montecucco for his helpful suggestions and Patrizia Ianes for her technical assistance in preparation of the manuscript.

Alessandro Picelli, MD,1,2 Nicola Smania, MD,1 Ilaria Storti, MD,1 Daniele Munari, PT,1 Carla Fontana, MD,1 Antonio Fiaschi, MD,1 Valter Santilli, MD,2,4 and Stefano Tamburin, MD, PhD3

1Neuromotor and Cognitive Rehabilitation Research Center, Department of Neurological Neuropsychological, Morphological and Movement Sciences, University of Verona, Verona, Italy; 2PhD course in Experimental Physical Medicine and Rehabilitation applied to Human Locomotor System, University of Rome “La Sapienza”, Rome, Italy; 3Department of Neurological, Neuropsychological Morphological and Movement Sciences Neurology Section, University of Verona Verona, Italy; and 4Department of Physical Medicine and Rehabilitation, University of Rome “La Sapienza”, Rome, Italy

References


Table 1. Outcome measures before and 4 weeks after injection

<table>
<thead>
<tr>
<th>Outcome measures</th>
<th>T0 Mean (SD)</th>
<th>T1 Mean (SD)</th>
<th>Within-group comparison (Wilcoxon signed ranks test)</th>
<th>Between-groups comparison (Mann-Whitney U test)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Group A</td>
<td>2.58 (0.90)</td>
<td>1.25 (0.97)</td>
<td>0.001 (−3.176)6</td>
<td>0.890 (−0.139) 0.015 (−2.439)8</td>
</tr>
<tr>
<td>Group B</td>
<td>2.50 (0.80)</td>
<td>1.67 (0.94)</td>
<td>0.002 (−3.162)6</td>
<td>0.862 (−0.173) 0.040 (−2.051)8</td>
</tr>
<tr>
<td>Group A</td>
<td>11.60 (4.00)</td>
<td>4.36 (2.77)</td>
<td>0.002 (−3.061)6</td>
<td></td>
</tr>
<tr>
<td>Group B</td>
<td>12.41 (4.15)</td>
<td>7.24 (3.87)</td>
<td>0.002 (−3.061)6</td>
<td></td>
</tr>
</tbody>
</table>

SD, standard deviation; MAS, Modified Ashworth Scale; CMAP, compound muscle action potential; ADM, abductor digiti minimi muscle.

aSignificant comparison (P < .05).

Movement Disorders, Vol. 26, No. 9, 2011